quinuclidines has been researched along with Cardiovascular Diseases in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R | 1 |
Brygger, L; Herrstedt, J | 1 |
Nagy, LB | 1 |
Kardos, P; Müllerová, H; Newby, DE; Román-Rodríguez, M; Singh, D; Worsley, S | 1 |
LEVIT, VG; SMULEVICH, AB | 1 |
de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U | 1 |
Doods, HN; van Zwieten, PA | 1 |
3 review(s) available for quinuclidines and Cardiovascular Diseases
Article | Year |
---|---|
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
[Are there cardiovascular adverse effects of inhaled anticholinergics?].
Topics: Administration, Inhalation; Bronchodilator Agents; Cardiovascular Diseases; Cardiovascular System; Cholinergic Antagonists; Clinical Trials as Topic; Glycopyrrolate; Humans; Incidence; Ipratropium; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide | 2015 |
Muscarinic receptors and drugs in cardiovascular medicine.
Topics: Bradycardia; Cardiovascular Diseases; Cholinergic Agents; Endothelium, Vascular; Humans; Muscarinic Agonists; Muscarinic Antagonists; Muscle, Smooth, Vascular; Nitric Oxide; Parasympatholytics; Pirenzepine; Quinuclidines; Receptors, Muscarinic; Regression Analysis; Structure-Activity Relationship | 1995 |
1 trial(s) available for quinuclidines and Cardiovascular Diseases
Article | Year |
---|---|
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Topics: Aged; Androstadienes; Benzyl Alcohols; Cardiovascular Diseases; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
3 other study(ies) available for quinuclidines and Cardiovascular Diseases
Article | Year |
---|---|
Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Cardiovascular Diseases; Chlorobenzenes; Comorbidity; Drug Combinations; Evidence-Based Medicine; Humans; Lung; Muscarinic Antagonists; Patient Safety; Patient Selection; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Tiotropium Bromide; Treatment Outcome | 2016 |
[USE OF OXYLIDINE IN THE AMBULATORY TREATMENT OF MENTAL PATIENTS].
Topics: Anxiety; Anxiety Disorders; Cardiovascular Diseases; Delusions; Depression; Guilt; Humans; Hypnotics and Sedatives; Hypochondriasis; Mentally Ill Persons; Meprobamate; Neurotic Disorders; Obsessive-Compulsive Disorder; Paranoid Disorders; Phobic Disorders; Quinuclidines; Schizophrenia; Tranquilizing Agents | 1963 |
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Female; Germany; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Product Surveillance, Postmarketing; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2008 |